A Clinical Management of Bronchial asthama

Clinical Evaluation of Kodagasalai Ennai in the treatment of Suzhimantham in children

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/08/004825

Enrollment

Registered

2014-08-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Intermittent fever, wheezing, lack of appetite

Interventions

Intervention1: KODAGASALAI ENNAI Internal drug for Suzhimaantham: KODAGASALAI ENNAI is a poly herbal drug- 160 mg- OD dose for 7 days. Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Intermittent fever Wheezing Insomnia Hiccough Lack of appetite Dyspnoea Indrawing of respiratory muscles

Exclusion criteria

Exclusion criteria: Jaundice Enteric fever Pneumonia Congenital heart disease Any other serious illness

Design outcomes

Primary

Measure	Time frame
Results and observation during the study inclusive of clinical improvementsTimepoint: 2-3 months	—

Secondary

Measure	Time frame
Results and observation during the study inclusive of clinical improvementsTimepoint: Before treatment and after treatment	—

Countries

India

Contacts

Public ContactMMeenakshi Sundaram

National Institute of Siddha

drelavarasanmd@gmail.com9952144747

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026